The negative findings of the previous studies can be explained by the hypothesis that other molecular pathways interfere with the EGFR/HER2 signalling, such as follicle stimulating hormone receptor (FSHR), potentially minimizing HER2 impact on ovarian cancer cell proliferation and ultimately to the HER2 effect on disease progression and prognosis. This evidence concerns the gene FSHR and ovarian cancer.